quinazolines has been researched along with rifampin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, H; Kusaba, T; Nagasawa, K; Otsuka, T; Sakata, T; Tada, Y; Tsuda, Y | 1 |
| Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ | 1 |
| Duvauchelle, T; Kennedy, SJ; Martin, P; Oliver, S; Read, J; Robertson, J | 1 |
| Adamson, D; Brown, K; Chen, E; Evans, TR; Hotte, S; Kollmansberger, C; Lassen, U; Meyer, T; Miller, WH; Nielsen, DL; Rafi, R; Sawyer, MB; Spicer, J | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Hardy, KD; Nelson, SD; Papageorgiou, I; Rettie, AE; Unadkat, JD; Wahlin, MD | 1 |
| Bertulis, J; Brand, T; Gansser, D; Giessmann, T; Hocke, J; Jungnik, A; Marzin, K; Stopfer, P; Wind, S | 1 |
| Drolet, DW; Fettner, SH; Hamilton, M; Lum, BL; Rakhit, AK; Witt, K; Wolf, JL | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, D; Zhao, Q; Zheng, X | 1 |
| Al-Huniti, N; Henningsson, A; Li, J; Masson, E; Tang, W | 1 |
| Kaur, R; Sharma, V; Sharma, VL | 1 |
| Choudhir, G; Kumar, A; Mishra, A; Pathak, Y; Tripathi, V | 1 |
| Chu, X; Fancourt, C; Iwamoto, M; Lassman, M; Marceau West, R; McCrea, JB; Menzel, K; Mostoller, K; Robbins, JA; Stoch, SA; Witter, R; Zhao, T | 1 |
| Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L | 1 |
5 trial(s) available for quinazolines and rifampin
| Article | Year |
|---|---|
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Topics: Adolescent; Adult; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Gefitinib; Humans; Itraconazole; Male; Metoprolol; Microsomes, Liver; Middle Aged; Neoplasms; Quinazolines; Rifampin | 2005 |
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Humans; Itraconazole; Male; Piperidines; Quinazolines; Rifampin | 2011 |
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Topics: Adult; Aged; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; Young Adult | 2013 |
Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Topics: Adolescent; Adult; Afatinib; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Male; Middle Aged; Quinazolines; Rifampin; Ritonavir; Young Adult | 2014 |
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
Topics: Adult; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Erlotinib Hydrochloride; Female; Healthy Volunteers; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rifampin; Young Adult | 2014 |
9 other study(ies) available for quinazolines and rifampin
| Article | Year |
|---|---|
Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Interactions; Ethambutol; Female; Humans; Hypertension; Isoniazid; Nicardipine; Nifedipine; Propranolol; Quinazolines; Rifampin | 1992 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Topics: Biotransformation; Cell Line, Tumor; Cell Survival; Cysteine; Cytochrome P-450 CYP3A; Dexamethasone; Glutathione; Hepatocytes; Humans; Lapatinib; Liver; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rifampin | 2014 |
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Topics: Antineoplastic Agents; Area Under Curve; Computer Simulation; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Ketoconazole; Male; Microsomes, Liver; Models, Biological; Quinazolines; Rifampin | 2015 |
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Body Weight; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Male; Middle Aged; Models, Biological; Neoplasms; Polypharmacy; Protein Kinase Inhibitors; Quinazolines; Rifampin; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
Ameliorative potential of Adhatoda vasica against anti-tubercular drugs induced hepatic impairments in female Wistar rats in relation to oxidative stress and xeno-metabolism.
Topics: Alkaloids; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; Cholesterol 7-alpha-Hydroxylase; Cytochrome P-450 CYP2E1; Disease Models, Animal; Female; Free Radical Scavengers; Gene Expression Regulation; Glucuronosyltransferase; Isoniazid; Justicia; Oxidative Stress; Plant Extracts; Plant Leaves; Pregnane X Receptor; Pyrazinamide; Quinazolines; Rats, Wistar; Rifampin | 2021 |
Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
Topics: Acetates; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Repositioning; Humans; Molecular Docking Simulation; Quinazolines; Rifampin; SARS-CoV-2; Viral Proteases | 2021 |
Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Topics: Acetates; Adolescent; Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers; Coproporphyrins; Cytochrome P-450 CYP3A; Drug Interactions; Female; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Middle Aged; Organic Anion Transporters; Quinazolines; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3; Young Adult | 2022 |
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide | 2022 |